首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >Assessment of Influential Variables in the Pricing of Locally Manufactured Pharmaceuticals: Current Challenging Situation in Iran
【2h】

Assessment of Influential Variables in the Pricing of Locally Manufactured Pharmaceuticals: Current Challenging Situation in Iran

机译:对本地制造制药定价的影响变量评估:伊朗当前挑战性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The lack of transparency and predictability seems to remain one of the major complaints in the pharmaceutical pricing procedure in Iran, but there is not enough official evidence to support it. The main objective of this study was to identify influential variables officially or unofficially influencing the pharmaceuticals pricing in Iran and also clarifying the degree of importance of each variable from the viewpoints of two groups: the pricing Commission members (owners of pricing procedure) and other stakeholders in the pharmaceutical sector. Semi-structured interviews with experts were performed to extract the influential variables. A Likert scale questionnaire was designed based on extracted variables and used in above-mentioned two groups of experts. The validity and reliability of the questionnaire were assessed before use. About 68 influential variables were extracted which classified into eight categories or domains. Less than 50% of extracted influential variables on pharmaceutical pricing have been mentioned in Iran pricing regulations. There were statistically significant differences between the two group’s viewpoints in terms of importance and effect of some variables on pricing procedure. Conflict of interest, lack of transparency and a sound framework were found as the main problems in Iran pharmaceutical pricing procedure and may lead to “case-by-case” decision making. As such, the output of the pricing commission is not transparent and predictable for its beneficiaries.
机译:缺乏透明度和可预测性似乎仍然是伊朗药物定价程序中的主要投诉之一,但没有足够的官方证据来支持它。本研究的主要目标是确定正式或非公开的影响变量,或者非正式地影响伊朗的药物定价,并从两组的观点澄清每个变量的重要性:定价委员会成员(定价程序的所有者)和其他利益攸关方在制药部门。对专家进行半结构化访谈以提取有影响力的变量。基于提取的变量设计了李克特规模问卷,并在上述两组专家中使用。在使用前评估问卷的有效性和可靠性。提取大约68个有影响力的变量,分为八个类别或域。在伊朗定价法规中提到了不到50%的药品定价的影响变量。两组在定价程序中一些变量的重要性和影响的观点之间存在统计学意义。利益冲突,缺乏透明度和声音框架被发现是伊朗药物定价程序的主要问题,可能导致“逐个案例”决策。因此,定价委员会的产出对其受益人来说并不透明和可预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号